Trabedersen sodium

Synonyms: AP 12009 sodium
Trabedersen (AP 12009) sodium 是一种口服有效的合成反义硫代磷酸寡脱氧核苷酸,可选择性靶向人源 TGFβ2 mRNA,通过阻断 TGFβ2 蛋白生成并无需转染载体即可进入细胞核发挥剂量依赖性抗肿瘤作用,同时通过逆转 TGFβ2 诱导的免疫抑制和增强免疫细胞毒性而表现出显著的抗增殖、抗迁移及抗转移活性,并显示出良好的安全性,因而被广泛用于间变性星形细胞瘤、胶质母细胞瘤、结直肠肿瘤及黑色素瘤等多种实体瘤的相关研究。
Trabedersen sodium
产品编号: MS-Y81087 纯度: 98.81% 分子式: C177H217N60Na18O94P17S17 分子量: 5768.7 (free acid)
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Trabedersen (AP 12009) sodium 是一种口服有效的合成反义硫代磷酸寡脱氧核苷酸,可选择性靶向人源 TGFβ2 mRNA,通过阻断 TGFβ2 蛋白生成并无需转染载体即可进入细胞核发挥剂量依赖性抗肿瘤作用,同时通过逆转 TGFβ2 诱导的免疫抑制和增强免疫细胞毒性而表现出显著的抗增殖、抗迁移及抗转移活性,并显示出良好的安全性,因而被广泛用于间变性星形细胞瘤、胶质母细胞瘤、结直肠肿瘤及黑色素瘤等多种实体瘤的相关研究。

生物实验数据

生物活性 Trabedersen (AP 12009) sodium is an orally effective synthetic antisense phosphorothioate oligodeoxynucleotide that selectively targets human TGFβ2 mRNA, blocks TGFβ2 protein production, and enters the nucleus without a transfection vector to exert dose-dependent antitumor effects; by reversing TGFβ2-induced immunosuppression and enhancing immune cytotoxicity, it exhibits significant antiproliferative, antimigratory, and antimetastatic activities with a favorable safety profile, and is therefore widely used in research on various solid tumors, including anaplastic astrocytoma, glioblastoma, colorectal tumors, and melanoma.
体外研究
(In Vitro)

Trabedersen sodium (1, 5, 10 μM) 可使人类高级别星形细胞瘤 (III/IV) 细胞的 TGFβ2 分泌量降低 49%-73%,细胞增殖能力降低 24%-41%,同时抑制细胞迁移并增强 LAK 细胞介导的细胞毒性。
Trabedersen sodium 可抑制 TGFβ2 分泌达 43%,将细胞增殖率最高降低 77%,阻断细胞迁移,并使人胰腺癌细胞系 (Hup-T3, PA-TU 8902) 中 LAK 细胞的细胞毒性提升 4 倍。
Trabedersen sodium (1-80 μM; 7 d) 可强效抑制人胰腺癌 Hup-T3 细胞的 TGF-β2 分泌,其 IC50 为 1.7 μM,且在处理 7 天后,浓度≥60 μM 时可实现完全抑制。
Trabedersen sodium (2.5-80 μM; 7 d) 可强烈抑制人胰腺癌 Hup-T3 细胞的增殖,其 IC50 为 4.6 μM,且处理 7 天后在 40 μM 浓度下抑制率>90%。
Trabedersen sodium (5 μM; 7 d) 在球状体模型中可完全抑制人胰腺癌 PA-TU-8902 细胞的迁移 (给药浓度 5 μM,作用时长最长 7 天)。
Trabedersen sodium (200 nM, 5 μM; 6 h, variable) 可有效逆转 TGF-β2 介导的人胰腺癌 Hup-T3 细胞免疫抑制作用,显著增强 LAK 细胞对 Hup-T3 靶细胞的细胞毒性。
Trabedersen sodium (10-80 μM) 可强效抑制多形性胶质母细胞瘤细胞中 TGF-β2 的分泌。

ELISA Assay

Cell Line: human pancreatic cancer Hup-T3 cells
Concentration: 1, 10, 20, 60, 80 μM
Incubation Time: 7 days (with medium replacement on days 2 and 4)
Result: Caused a concentration-dependent reduction of TGF-β2 secretion.
Achieved >30% reduction with 1 μM trabedersen.
Achieved >95% reduction with 20 μM trabedersen.
Resulted in no detectable TGF-β2 at concentrations ≥60 μM.
Had an IC50 of 1.7 μM for TGF-β2 secretion inhibition.

Cell Proliferation Assay

Cell Line: human pancreatic cancer Hup-T3 cells
Concentration: 2.5, 10, 20, 40, 60, 80 μM
Incubation Time: 7 days (with medium replacement on days 2 and 4)
Result: Caused a concentration-dependent reduction in Hup-T3 cell number.
Achieved >90% reduction in cell number with 40 μM trabedersen.
Had an IC50 of 4.6 μM for inhibition of Hup-T3 cell proliferation.
体内研究
(In Vivo)

Trabedersen sodium (1.4-50 nmol;鞘内给药;单次推注剂量;5 nmol/h;脑内给药;持续输注;1 周) sodium 对兔和食蟹猴鞘内单次推注最高 50 nmol 的剂量耐受性良好,而以 5 nmol/h 的速率脑内持续输注 1 周会在兔体内引发轻度至中度的局部白细胞浸润。
Trabedersen (30-1000 mg/kg;静脉注射;单次推注剂量) sodium 在小鼠和大鼠中单次静脉推注剂量高达 100 mg/kg 时耐受性良好,其小鼠的 LD50 值为 706 mg/kg,大鼠的 LD50 值为 1175 mg/kg。
Trabedersen sodium 以 1 mg/kg/天的剂量持续静脉输注在大鼠和猴体内具有良好的耐受性,而更高剂量的持续输注会引发可逆性炎症和组织损伤;以 8 mg/kg 的剂量隔日静脉输注、持续 4 周在猴体内同样具有良好的耐受性。
Trabedersen (5-160 mg/kg;静脉注射;持续 2 h;单次给药) sodium 在食蟹猴中,针对心血管及补体激活终点指标,持续 2 h 的静脉给药剂量在 20 mg/kg 以内耐受性良好;针对血液学指标,给药剂量在 5 mg/kg 以下时耐受性良好。
Trabedersen (0.25-50 mg/kg;腹腔注射;每周 3 次;约 32-35 天) sodium 在原位异种移植黑色素瘤小鼠模型中展现出强效的剂量依赖性抗肿瘤活性,可减少肺转移,且具有免疫调节作用以及细胞/细胞核摄取的证据;其中 50/16 mg/kg 给药方案可使平均肿瘤重量显著降低至 0.395 g。
Trabedersen sodium 可显著降低原位异种移植小鼠模型中原发胰腺癌的肿瘤重量、肿瘤细胞增殖水平、肿瘤血管化程度及淋巴结转移发生率。

Animal Model: New Zealand White rabbits; Cynomolgus monkeys
Dosage: 1.4 nmol (intrathecal bolus); 50 nmol (intrathecal bolus); 5 nmol/h (continuous intracerebral infusion)
Administration: intrathecal; single bolus dose; intracerebral; continuous infusion; 1 week
Result: Reported no clinical signs of toxicity after single intrathecal bolus doses of 1.4 nmol or 50 nmol.
Detected no macroscopic drug-related toxicity after continuous intracerebral infusion of 5 nmol/h for 1 week, but histopathology revealed mild-to-moderate leukocyte infiltration near the injection site.
Animal Model: Rats; Cynomolgus monkeys
Dosage: 1 mg/kg/day (continuous intravenous infusion); 4 mg/kg/day (continuous intravenous infusion); 16 mg/kg/day (continuous intravenous infusion); 8 mg/kg (intravenous over 4 h)
Administration: intravenous; continuous infusion; 2 weeks (rats); 2-4 weeks (monkeys); intravenous; over 4 h; every other day; 4 weeks
Result: Detected no adverse effects in rats or monkeys treated with 1 mg/kg/day continuous intravenous infusion.
Observed evidence of inflammation and tissue damage at higher continuous infusion doses (4 mg/kg/day, 16 mg/kg/day), including increased erythrocyte sedimentation rate, increased activated partial thromboplastin time, decreased platelet counts, increased blood AST levels, decreased albumin and calcium levels, decreased albumin/globulin ratio, and histological lesions in the liver and kidneys; these lesions were almost completely repaired after a 4-week recovery period.
Noted no significant hematological or biochemical changes in monkeys treated with 8 mg/kg intravenous over 4 h every other day for 4 weeks.
Animal Model: BALB/c nu/nu mice
Dosage: 50 mg/kg initial dose followed by 16 mg/kg subsequent doses; 16 mg/kg; 4 mg/kg; 1 mg/kg; 0.25 mg/kg
Administration: i.p.; thrice weekly; approximately 32-35 days
Result: Reduced mean tumor weight to 0.395 g in mice treated with 50/16 mg/kg regimen compared to controls.
Exhibited dose-dependent reduction in tumor weight and tumor growth at doses of 1 mg/kg, 4 mg/kg, and 16 mg/kg.
Significantly inhibited lung metastasis.
Showed a trend toward fewer monocytic MDSCs in spleens, with no differences in granulocytic MDSCs or NK cells compared to controls.
Demonstrated clear intracellular and intranuclear fluorescence in all tumor sections from mice receiving intratumoral fluorescently labeled trabedersen, confirming cellular and nuclear uptake.
Animal Model: BALB/Cnu/nu mice (8-week-old male, orthotopic pancreatic cancer xenograft model)
Dosage: 50 mg/kg (initial loading dose); 16 mg/kg (maintenance)
Administration: i.p.; single initial loading dose on day 2 post-tumor implantation; three times weekly (Monday, Wednesday, Friday)
Result: Reduced mean primary tumor.
Significantly decreased tumor cell proliferation.
Reduced tumor vascularization to approximately one-third of control levels (CD31+ vessel area).
Reduced lymph node metastasis incidence from 7 out of 9 to 2 out of 10.
Showed no significant effect on liver metastasis incidence.
性状 固体
颜色 White to off-white

化学信息

分子量 5768.7 (free acid)
分子式 C177H217N60Na18O94P17S17
别名 AP 12009 sodium

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础